References
Capelli, A. M., Castelletti, L., Chen, Y. H., Van der Keyl, H., Pucci,
L., Oliosi, B., . . . Powell, A. (2011). Stable expression and
functional characterization of a human nicotinic acetylcholine receptor
with α6β2 properties: Discovery of selective antagonists. British
Journal of Pharmacology, 163 (2), 313-329.
Chang, P., Chiang, C., Ho, W., Wu, P., Tsai, J., & Guo, F. (2015).
Combination therapy of varenicline with nicotine replacement therapy is
better than varenicline alone: A systematic review and meta-analysis of
randomized controlled trials. BMC Public Health, 15 (1), 1-8.
Chavez-Noriega, L. E., Crona, J. H., Washburn, M. S., Urrutia, A.,
Elliott, K. J., & Johnson, E. C. (1997). Pharmacological
characterization of recombinant human neuronal nicotinic acetylcholine
receptors hα2β2, hα2β4, hα3β2, hα3β4, hα4β2, hα4β4 and hα7 expressed in
xenopus oocytes. Journal of Pharmacology and Experimental
Therapeutics, 280 (1), 346-356.
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P.,
Huang, J., . . . Fox, C. B. (2005). Varenicline: An α4β2 nicotinic
receptor partial agonist for smoking cessation. Journal of
Medicinal Chemistry, 48 (10), 3474-3477.
Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C.
H., Giembycz, M. A., . . . Ji, Y. (2018). Experimental design and
analysis and their reporting II: Updated and simplified guidance for
authors and peer reviewers. British Journal of Pharmacology,
175 (7), 987-993.
Di Angelantonio, S., Matteoni, C., Fabbretti, E., & Nistri, A. (2003).
Molecular biology and electrophysiology of neuronal nicotinic receptors
of rat chromaffin cells. European Journal of Neuroscience,
17 (11), 2313-2322.
Faessel, H. M., Gibbs, M. A., Clark, D. J., Rohrbacher, K., Stolar, M.,
& Burstein, A. H. (2006). Multiple‐dose pharmacokinetics of the
selective nicotinic receptor partial agonist, varenicline, in healthy
smokers. The Journal of Clinical Pharmacology, 46 (12), 1439-1448.
Gershon, A. S., Campitelli, M. A., Hawken, S., Victor, C., Sproule, B.
A., Kurdyak, P., & Selby, P. (2018). Cardiovascular and
neuropsychiatric events after varenicline use for smoking cessation.American Journal of Respiratory and Critical Care Medicine,
197 (7), 913-922.
Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S.,
Billing, C. B., . . . Reeves, K. R. (2006). Varenicline, an α4β2
nicotinic acetylcholine receptor partial agonist, vs sustained-release
bupropion and placebo for smoking cessation: A randomized controlled
trial. Jama, 296 (1), 47-55.
Gourlay, S. G., & Benowitz, N. L. (1997). Arteriovenous differences in
plasma concentration of nicotine and catecholamines and related
cardiovascular effects after smoking, nicotine nasal spray, and
intravenous nicotine. Clinical Pharmacology & Therapeutics,
62 (4), 453-463.
Hone, A. J., M. Ruiz, M. Scadden, S. Christensen, J. Gajewiak, L. Azam
and J. M. McIntosh (2013). Positional scanning mutagenesis of
alpha-conotoxin PeIA identifies critical residues that confer potency
and selectivity for alpha6/alpha3beta2beta3 and alpha3beta2 nicotinic
acetylcholine receptors. Journal of Biological Chemistry,288 (35), 25428-25439.
Hone, A. J., McIntosh, J. M., Azam, L., Lindstrom, J., Lucero, L.,
Whiteaker, P., . . . Albillos, A. (2015). α-conotoxins identify the
α3β4* subtype as the predominant nicotinic acetylcholine receptor
expressed in human adrenal chromaffin cells. Molecular
Pharmacology, 88 (5), 881-893.
Hone, A. J., McIntosh, J.M., Rueda‐Ruzafa, L., Passas, J., de
Castro‐Guerín, C., Blázquez, J., . . . Albillos, A. (2017). Therapeutic
concentrations of varenicline in the presence of nicotine increase
action potential firing in human adrenal chromaffin cells. Journal
of Neurochemistry, 140 (1), 37-52.
Hone, A. J., Rueda‐Ruzafa, L., Gordon, T. J., Gajewiak, J., Christensen,
S., Dyhring, T., . . . McIntosh, J. M. (2020). Expression of α3β2β4
nicotinic acetylcholine receptors by rat adrenal chromaffin cells
determined using novel conopeptide antagonists. Journal of
Neurochemistry, 154 (2):158-176.
Hukkanen, J., Ukkola, O., & Benowitz, N. L. (2010). Varenicline and
pheochromocytoma. Annals of Internal Medicine, 152 (5), 335-336.
Jorenby, D. E., Hays, J. T., Rigotti, N. A., Azoulay, S., Watsky, E. J.,
Williams, K. E., . . . Varenicline Phase 3 Study Group. (2006). Efficacy
of varenicline, an α4β2 nicotinic acetylcholine receptor partial
agonist, vs placebo or sustained-release bupropion for smoking
cessation: A randomized controlled trial. Jama, 296 (1), 56-63.
Kikkawa, H., Maruyama, N., Fujimoto, Y., & Hasunuma, T. (2011).
Single‐and multiple‐dose pharmacokinetics of the selective nicotinic
receptor partial agonist, varenicline, in healthy japanese adult
smokers. The Journal of Clinical Pharmacology, 51 (4), 527-537.
Luo, S., Zhangsun, D., Zhu, X., Wu, Y., Hu, Y., Christensen, S., . . .
McIntosh, J. M. (2013). Characterization of a novel α-conotoxin TxID
from conus textile that potently blocks rat α3β4 nicotinic acetylcholine
receptors. Journal of Medicinal Chemistry, 56 (23), 9655-9663.
Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006). Varenicline is
a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic
receptors. Molecular Pharmacology, 70 (3), 801-805.
Moro, M. A., López, M. G., Gandía, L., Michelena, P., & Garcia, A. G.
(1990). Separation and culture of living adrenaline-and
noradrenaline-containing cells from bovine adrenal medullae.Analytical Biochemistry, 185 (2), 243-248.
Mosharov, E. V., & Sulzer, D. (2005). Analysis of exocytotic events
recorded by amperometry. Nature Methods, 2 (9), 651-658.
Munarini, E., Marabelli, C., Pozzi, P., & Boffi, R. (2015). Extended
varenicline treatment in a severe cardiopathic cigarette smoker: A case
report. Journal of Medical Case Reports, 9 (1), 1-4.
Pérez‐Alvarez, A., & Albillos, A. (2007). Key role of the nicotinic
receptor in neurotransmitter exocytosis in human chromaffin cells.Journal of Neurochemistry, 103 (6), 2281-2290.
Pérez‐Alvarez, A., Hernández‐Vivanco, A., Alonso y Gregorio, S.,
Tabernero, A., McIntosh, J. M., & Albillos, A. (2012a). Pharmacological
characterization of native α7 nicotinic ACh receptors and their
contribution to depolarization‐elicited exocytosis in human chromaffin
cells. British Journal of Pharmacology, 165 (4), 908-921.
Pérez‐Alvarez, A., Hernández‐Vivanco, A., McIntosh, J. M., & Albillos,
A. (2012b). Native α6β4* nicotinic receptors control exocytosis in human
chromaffin cells of the adrenal gland. FASEB J. 26(1):346-54.
Prochaska, J. J., & Hilton, J. F. (2012). Risk of cardiovascular
serious adverse events associated with varenicline use for tobacco
cessation: Systematic review and meta-analysis. Bmj, 344 , e2856.
Ravva, P., Gastonguay, M. R., Tensfeldt, T. G., & Faessel, H. M.
(2009). Population pharmacokinetic analysis of varenicline in adult
smokers. British Journal of Clinical Pharmacology, 68 (5),
669-681.
Rigotti, N.A., Pipe, A.L., Benowitz, N.L., Arteaga, C., Garza, D.,
Tonstad, S. (2010)
Efficacy and safety of
varenicline for smoking cessation in patients with cardiovascular
disease: a randomized trial. Circulation 121 (2):221-9.
Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S.,
Lebel, L. A., . . . Rovetti, C. C. (2007). Pharmacological profile of
the α4β2 nicotinic acetylcholine receptor partial agonist varenicline,
an effective smoking cessation aid. Neuropharmacology, 52 (3),
985-994.
Selçuk, E. B., Sungu, M., Parlakpinar, H., Ermiş, N., Taslıdere, E.,
Vardı, N., . . . Karatas, M. (2015). Evaluation of the cardiovascular
effects of varenicline in rats. Drug Design, Development and
Therapy, 9 , 5705.
Singh, S., Loke, Y. K., Spangler, J. G., & Furberg, C. D. (2011). Risk
of serious adverse cardiovascular events associated with varenicline: A
systematic review and meta-analysis. Cmaj, 183 (12), 1359-1366.
Tammimäki, A., Herder, P., Li, P., Esch, C., Laughlin, J. R., Akk, G.,
& Stitzel, J. A. (2012). Impact of human D398N single nucleotide
polymorphism on intracellular calcium response mediated by α3β4α5
nicotinic acetylcholine receptors. Neuropharmacology, 63 (6),
1002-1011.
Whiteaker, P., Christensen, S., Yoshikami, D., Dowell, C., Watkins, M.,
Gulyas, J., . . . McIntosh, J. M. (2007). Discovery, synthesis, and
structure activity of a highly selective alpha7 nicotinic acetylcholine
receptor antagonist. Biochemistry 46 (22),
6628-6638.
Wightman, R. M., Jankowski, J. A., Kennedy, R. T., Kawagoe, K. T.,
Schroeder, T. J., Leszczyszyn, . . . Viveros, O. H. (1991) Temporally
resolved catecholamine spikes correspond to single vesicle release from
individual chromaffin cells. Proc Natl Acad Sci U S A,88(23),10754-8.